About Bioline  All Journals  Testimonials  Membership  News

Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613
EISSN: 0253-7613
Vol. 43, No. 2, 2011, pp. 105-112
Bioline Code: ph11034
Full paper language: English
Document type: Symposium
Document available free of charge

Indian Journal of Pharmacology, Vol. 43, No. 2, 2011, pp. 105-112

 en Newer molecules in the treatment of schizophrenia: A clinical update
Ghosh, Abhishek; Chakraborty, Kaustav & Mattoo, Surendra Kumar


Schizophrenia is a heterogeneous psychiatric disorder in which multiple neurotransmitter systems have been implicated. Increased and decreased dopamine transmission in the subcortical meso-limbic and meso-cortical systems is closely linked to the "positive" and "negative" symptoms of schizophrenia, respectively. Important roles have also been found for serotonin and acetylcholine, both of which are closely linked to dopamine. An abnormality in glutamate functioning involving N-methyl-D-aspartic acid as well as other receptor subtypes may underlie the dopamine dysfunction observed in schizophrenia. Since the discovery of chlorpromazine in 1952, researchers have been developing new molecules targeting various neurotransmitter systems to maximize their efficacy and tolerability. The advancements in molecular genetics have opened up new horizons to manipulate the post-receptor protein cascade and gene expression. Although the magic-wand still eludes us, the newer molecules hold a lot of promise in this condition.

Drugs, molecules, neurotransmitters, novel, schizophrenia

© Copyright 2011 Indian Journal of Pharmacology.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil